175 related articles for article (PubMed ID: 18771795)
1. Reversal of the inhibitory effect of fondaparinux on thrombin generation by rFVIIa, aPCC and PCC.
Desmurs-Clavel H; Huchon C; Chatard B; Negrier C; Dargaud Y
Thromb Res; 2009 Mar; 123(5):796-8. PubMed ID: 18771795
[TBL] [Abstract][Full Text] [Related]
2. Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography.
Young G; Yonekawa KE; Nakagawa PA; Blain RC; Lovejoy AE; Nugent DJ
Blood Coagul Fibrinolysis; 2007 Sep; 18(6):547-53. PubMed ID: 17762530
[TBL] [Abstract][Full Text] [Related]
3. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro.
Perzborn E; Heitmeier S; Laux V; Buchmüller A
Thromb Res; 2014 Apr; 133(4):671-81. PubMed ID: 24529498
[TBL] [Abstract][Full Text] [Related]
4. Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro.
Gatt A; van Veen JJ; Woolley AM; Kitchen S; Cooper P; Makris M
Thromb Haemost; 2008 Aug; 100(2):350-5. PubMed ID: 18690358
[TBL] [Abstract][Full Text] [Related]
5. Inactivated antithrombins as fondaparinux antidotes: a promising alternative to haemostatic agents as assessed in vitro in a thrombin-generation assay.
Bourti Y; Fazavana J; Armand M; Saller F; Lasne D; Borgel D; Bianchini EP
Thromb Haemost; 2016 Aug; 116(3):452-60. PubMed ID: 27412396
[TBL] [Abstract][Full Text] [Related]
6. Reversal of new, factor-specific oral anticoagulants by rFVIIa, prothrombin complex concentrate and activated prothrombin complex concentrate: a review of animal and human studies.
Lee FM; Chan AK; Lau KK; Chan HH
Thromb Res; 2014 May; 133(5):705-13. PubMed ID: 24666649
[TBL] [Abstract][Full Text] [Related]
7. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers.
Bijsterveld NR; Moons AH; Boekholdt SM; van Aken BE; Fennema H; Peters RJ; Meijers JC; Büller HR; Levi M
Circulation; 2002 Nov; 106(20):2550-4. PubMed ID: 12427650
[TBL] [Abstract][Full Text] [Related]
8. Antithrombin affects hemostatic response to recombinant activated factor VII in factor VIII deficient plasma.
Szlam F; Taketomi T; Sheppard CA; Kempton CL; Levy JH; Tanaka KA
Anesth Analg; 2008 Mar; 106(3):719-24, table of contents. PubMed ID: 18292408
[TBL] [Abstract][Full Text] [Related]
9. Effects of factor VIII inhibitor bypassing activity (FEIBA), recombinant factor VIIa or both on thrombin generation in normal and haemophilia A plasma.
Livnat T; Martinowitz U; Zivelin A; Seligsohn U
Haemophilia; 2008 Jul; 14(4):782-6. PubMed ID: 18371162
[TBL] [Abstract][Full Text] [Related]
10. Reversing anticoagulants both old and new.
Warkentin TE; Crowther MA
Can J Anaesth; 2002; 49(6):S11-25. PubMed ID: 12557411
[TBL] [Abstract][Full Text] [Related]
11. A direct thrombin inhibitor studied by dynamic whole blood clot formation. Haemostatic response to ex-vivo addition of recombinant factor VIIa or activated prothrombin complex concentrate.
Sørensen B; Ingerslev J
Thromb Haemost; 2006 Oct; 96(4):446-53. PubMed ID: 17003921
[TBL] [Abstract][Full Text] [Related]
12. Reversal of dabigatran effects in models of thrombin generation and hemostasis by factor VIIa and prothrombin complex concentrate.
Hoffman M; Volovyk Z; Monroe DM
Anesthesiology; 2015 Feb; 122(2):353-62. PubMed ID: 25502064
[TBL] [Abstract][Full Text] [Related]
13. Recombinant factor VIIa partially reverses the inhibitory effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood.
Gerotziafas GT; Depasse F; Chakroun T; Samama MM; Elalamy I
Thromb Haemost; 2004 Mar; 91(3):531-7. PubMed ID: 14983229
[TBL] [Abstract][Full Text] [Related]
14. More efficient reversal of dabigatran inhibition of coagulation by activated prothrombin complex concentrate or recombinant factor VIIa than by four-factor prothrombin complex concentrate.
Lindahl TL; Wallstedt M; Gustafsson KM; Persson E; Hillarp A
Thromb Res; 2015 Mar; 135(3):544-7. PubMed ID: 25596769
[TBL] [Abstract][Full Text] [Related]
15. Elevated factor VIII enhances thrombin generation in the presence of factor VIII-deficiency, factor XI-deficiency or fondaparinux.
Szlam F; Sreeram G; Solomon C; Levy JH; Molinaro RJ; Tanaka KA
Thromb Res; 2011 Feb; 127(2):135-40. PubMed ID: 21144556
[TBL] [Abstract][Full Text] [Related]
16. Ex vivo reversal of the anticoagulant effects of edoxaban.
Halim AB; Samama MM; Mendell J
Thromb Res; 2014 Oct; 134(4):909-13. PubMed ID: 25179520
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of prothrombin complex concentrate to reverse the anticoagulant effect of the pentasaccharide fondaparinux in a rabbit model.
Godier A; Durand M; Emmerich J; Dizier B; Lecompte T; Samama CM
Thromb Haemost; 2011 Jan; 105(1):161-8. PubMed ID: 20941458
[TBL] [Abstract][Full Text] [Related]
18. Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux.
Lisman T; Bijsterveld NR; Adelmeijer J; Meijers JC; Levi M; Nieuwenhuis HK; De Groot PG
J Thromb Haemost; 2003 Nov; 1(11):2368-73. PubMed ID: 14629471
[TBL] [Abstract][Full Text] [Related]
19. Effects of agents, used to treat bleeding disorders, on bleeding time prolonged by a very high dose of a direct thrombin inhibitor in anesthesized rats and rabbits.
Elg M; Carlsson S; Gustafsson D
Thromb Res; 2001 Feb; 101(3):159-70. PubMed ID: 11228339
[TBL] [Abstract][Full Text] [Related]
20. Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor.
Elg M; Carlsson S; Gustafsson D
Thromb Res; 2001 Feb; 101(3):145-57. PubMed ID: 11228338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
